New obesity drug to be used in Kyrgyzstan
The biopharmaceutical company Promomed has received a registration certificate in Kyrgyzstan for Tirzetta, a drug intended for the treatment of obesity. Vedomosti reported.
The drug’s active ingredient is tirzepatide. It is a first-in-class dual agonist of GLP-1 and GIP receptors; this mechanism allows the drug to suppress appetite, promote weight loss—primarily through the reduction of adipose tissue—and help maintain blood glucose levels within the target range.
According to the report, no similar medications were available in Kyrgyzstan prior to the registration of Tirzetta.
The company states that tirzepatide is manufactured using a full-cycle process at Biokhimik facility in Saransk. The drug is free from preservatives—such as phenol and benzyl alcohol—that could otherwise accumulate in the body during long-term therapy and potentially cause adverse effects.
It is worth noting that, according to 2024 WHO data, 56 percent of the country’s adult population is overweight, compared to a global average of 45 percent.